Clinical Trial Update: Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating menstrual blood-derived cell therapy for treating acute lung injury and ARDS caused by H7N9 bird flu infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Multiple Organ Failure
• Respiratory Distress Syndrome

Drugs mentioned

• Menstrual blood-derived cell therapy (menstrual blood-derived cell therapy)

Snippet

Sponsor: S-Evans Biosciences Co., Ltd. | Conditions: Acute Lung Injury, Acute Respiratory Distress Syndrome (ARDS) | Phase 1, Phase 2 | Status: UNKNOWN